Dual PI3K/mTOR Inhibitors Induce Rapid Overactivation of the MEK/ERK Pathway in Human Pancreatic Cancer Cells through Suppression of mTORC2.
about
Targeting mTOR in Pancreatic Ductal AdenocarcinomaPotentiation of Growth Inhibitory Responses of the mTOR Inhibitor Everolimus by Dual mTORC1/2 Inhibitors in Cultured Breast Cancer Cell LinesActivin and TGFβ use diverging mitogenic signaling in advanced colon cancerInhibition of autophagy sensitizes malignant pleural mesothelioma cells to dual PI3K/mTOR inhibitorsMolecular signature of pancreatic adenocarcinoma: an insight from genotype to phenotype and challenges for targeted therapy.Plasma microRNA panels to diagnose pancreatic cancer: Results from a multicenter studyPhospho-Akt overexpression is prognostic and can be used to tailor the synergistic interaction of Akt inhibitors with gemcitabine in pancreatic cancer.Blockade efficacy of MEK/ERK-dependent autophagy enhances PI3K/Akt inhibitor NVP-BKM120's therapeutic effectiveness in lung cancer cellsDual inhibition of the PI3K/AKT/mTOR pathway suppresses the growth of leiomyosarcomas but leads to ERK activation through mTORC2: biological and clinical implications.Targeting RAS-mutant cancers: is ERK the key?Association of BAFF with PI3K/Akt/mTOR signaling in lupus nephritis.Effects of Metformin and a Mammalian Target of Rapamycin (mTOR) ATP-Competitive Inhibitor on Targeted Metabolomics in Pancreatic Cancer Cell Line.Targeting ERK enhances the cytotoxic effect of the novel PI3K and mTOR dual inhibitor VS-5584 in preclinical models of pancreatic cancerInhibition of mTOR's Catalytic Site by PKI-587 Is a Promising Therapeutic Option for Gastroenteropancreatic Neuroendocrine Tumor Disease.New insights in the development of pancreatic cancer.Emerging protein kinase inhibitors for treating pancreatic cancer.HIF-2α regulates non-canonical glutamine metabolism via activation of PI3K/mTORC2 pathway in human pancreatic ductal adenocarcinoma.KRAS, YAP, and obesity in pancreatic cancer: A signaling network with multiple loops.ERK inhibition sensitizes CZ415-induced anti-osteosarcoma activity in vitro and in vivo.Cucurbitacin B and SCH772984 exhibit synergistic anti-pancreatic cancer activities by suppressing EGFR, PI3K/Akt/mTOR, STAT3 and ERK signaling.KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer.Dual Inhibition of PI3K/Akt and mTOR by the Dietary Antioxidant, Delphinidin, Ameliorates Psoriatic Features In Vitro and in an Imiquimod-Induced Psoriasis-Like Disease in Mice.Integrative landscape of dysregulated signaling pathways of clinically distinct pancreatic cancer subtypesHDAC6 inhibitor TST strengthens the antiproliferative effects of PI3K/mTOR inhibitor BEZ235 in breast cancer cells via suppressing RTK activation
P2860
Q26747291-4498A7E6-FE5C-4ECE-96F6-922036E7849FQ28546221-A72397CC-6051-452B-A3CE-44429AE80CCDQ36203725-52E44BB9-A256-44E2-AD3F-47D2DF379B08Q36346942-7D308C22-66AD-4A1C-A14D-F71F632A9B69Q37176648-49363171-5A98-41DD-A567-1085A93BB543Q37520294-F72BECAA-86C5-4D2C-B7E9-C3B62AA00E85Q37569554-B8A3015B-8FED-4D66-9D81-D3F617D2BDEEQ37687154-804E33BF-FD5C-491F-A944-65DF4C75007EQ37702626-522F3351-C3D6-4060-AB63-222AA38F9407Q38267209-07E7E888-1619-494D-A61C-B39D3E3AEA30Q38604547-C88B9353-62C1-4864-B415-F7558D6AB78DQ38715697-69D468B5-5488-48B5-94B2-126C4C491139Q38748709-63987820-14AD-46C1-B90C-E0E3036D8C7DQ38752443-7E70B93A-CCC4-4542-8888-3D968819180BQ38907393-1F3B6CCA-C5FA-4ABB-8E3D-CB36F67622F5Q39158411-AB352A6A-0590-4D09-9FB0-EBDAD178E0CDQ44272037-35CD9AE4-81FB-42DF-B06F-614E7509131CQ46471150-A6F8CC65-16E5-4A28-8E24-7E3FA841463AQ47103348-7CDC2C38-D33B-49CD-8DF3-9BC29B1AF8D9Q47141971-392E16D1-CA22-452B-A6DB-0A960152AB71Q47563012-7406FBCA-D548-4435-A186-D4BC239A9D07Q51653442-C828F2F9-185E-444D-9779-DC2093FF0CC0Q57263190-5D7476A9-4389-4972-8386-B38A5BCD7174Q58751858-09D923F3-0E2A-416B-B152-70EA4D2FFECA
P2860
Dual PI3K/mTOR Inhibitors Induce Rapid Overactivation of the MEK/ERK Pathway in Human Pancreatic Cancer Cells through Suppression of mTORC2.
description
2015 nî lūn-bûn
@nan
2015 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Dual PI3K/mTOR Inhibitors Indu ...... through Suppression of mTORC2.
@ast
Dual PI3K/mTOR Inhibitors Indu ...... through Suppression of mTORC2.
@en
type
label
Dual PI3K/mTOR Inhibitors Indu ...... through Suppression of mTORC2.
@ast
Dual PI3K/mTOR Inhibitors Indu ...... through Suppression of mTORC2.
@en
prefLabel
Dual PI3K/mTOR Inhibitors Indu ...... through Suppression of mTORC2.
@ast
Dual PI3K/mTOR Inhibitors Indu ...... through Suppression of mTORC2.
@en
P2093
P2860
P1476
Dual PI3K/mTOR Inhibitors Indu ...... through Suppression of mTORC2.
@en
P2093
Enrique Rozengurt
Heloisa P Soares
James Sinnet-Smith
Michelle Mellon
Steven H Young
P2860
P304
P356
10.1158/1535-7163.MCT-14-0669
P577
2015-02-11T00:00:00Z